arrow
N

Nadim J. Ajami

The University of Texas MD Anderson Cancer Center
H指数:74
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Colitis-Associated Colorectal Cancer—STAT3 Inhibition as a Preventive Strategy

结肠炎相关结直肠癌—STAT3抑制作为一种预防策略

2026-09-210
OA
Microbial signals in primary and metastatic brain tumors

原发性和转移性脑肿瘤中的微生物信号

2025-11-140
OAAI
Antibodies derived from patient tumors augment response to immune checkpoint blockade in cancer
2025-11-010
PRE
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest

肿瘤浸润细菌破坏癌症上皮细胞相互作用并诱导细胞周期停滞

2025-10-160
OAAI
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy

癌症诱导的神经损伤促进抗PD-1疗法的耐药性

Nature
IF48.5
2025-08-200
OA
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial

在抗PD-L1治疗的 Newly Diagnosed Glioblastoma 患者队列中,总体生存率的改善与特定的免疫、突变和肠道微生物组特征相关:一项单臂前瞻性I/II期试验

2025-04-270
OA
The bacterial microbiome modulates the initiation of brain metastasis by impacting the gut-to-brain axis

肠道菌群通过影响肠-脑轴来调节脑转移的启动。

2025-02-010
OAAI
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study

免疫效应细胞治疗后针对白喉、破伤风和肺炎球菌的体液免疫和抗体反应: 一项前瞻性研究

2024-09-190
OAAI
Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract

第三方粪便微生物移植用于高风险治疗-下消化道的急性GVHD

2024-04-264
OAAI
Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation trial for metastatic melanoma demonstrates impact of antibiotic pre-conditioning regimen on the microbiome and immunity
2024-04-050
PRE
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity

黑色素瘤中随机安慰剂对照、生物标志物分层Ib期微生物组调节: 抗生素预处理对微生物组和免疫的影响

2024-04-032
OAAI
Cancer testis antigen expression correlates with stromal natural killer cell activation and longer overall survival in small bowel neuroendocrine tumors
2024-03-220
PRE